GraceFinance · Source-backed public company research
Rein Therapeutics, Inc. (RNTX)
Nasdaq · Manufacturing · Pharmaceutical Preparations
Core research established · 4/4 core data layers currently established
What Rein Therapeutics, Inc. does
Overview and Recent Developments We are a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. We currently have two product candidates in clinical development, LTI-03 and LTI-01, however, due to insufficient funding we have paused development of LTI‑01 for an undetermined period of time and are prioritizing LTI‑03.
Open the company story
The live GraceFinance page shows source-backed financial changes, management context, guidance, confirmed events, risks, and connected history only when the applicable evidence and relationships have been established. Missing research stays visible instead of being inferred.